Immune Pharmaceuticals Announces Strategic Partnership With the World-Renowned Weizmann Institute

Published: May 23, 2012

HERZLIYA and REHOVOT, Israel, May 23, 2012 (GLOBE NEWSWIRE) -- IMMUNE Pharmaceuticals, an emerging leader in the development of monoclonal antibodies, and Yeda, the technology transfer company of the Weizmann Institute of Science, announced today a broad collaboration to develop antibody therapeutics targeting HER3, one of the most promising novel targets in oncology with early clinical validation.

Back to news